Potomac, Maryland, United States In 2007 was created jVen Capital, which is appeared as VC. The company was established in North America in United States. The main department of described VC is located in the Potomac.
The current fund was established by Evan Jones. Besides them, we counted 1 critical employee of this fund in our database.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2015. The high activity for fund was in 2012. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the jVen Capital, startups are often financed by Versant Ventures, Mason Wells, Highland Capital Partners. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Highland Capital Partners, CHL Medical Partners. In the next rounds fund is usually obtained by Versant Ventures, Highland Capital Partners, Cross Creek.
Among the most popular fund investment industries, there are Health Care, Genetics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight OpGen. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Archer Venture Capital | California, Los Angeles, United States |
| Astrolabe Ventures | California, Palo Alto, United States |
| Broadcom | California, San Jose, United States |
| marquee angels | - |
| NAXOS Capital Partners | France, Ile-de-France, Paris |
| NTT Communications | Japan, Tokyo |
| Velux Foundation | Denmark, Hovedstaden, Søborg |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Kyverna Therapeutics | $60M | 03 Aug 2023 | Berkeley, California, United States | ||
Kyverna Therapeutics | $85M | 26 Jan 2022 | Berkeley, California, United States | ||
OpGen | $17M | 07 Mar 2012 | Maryland, United States | ||
OpGen | $17M | 28 Sep 2010 | Maryland, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Kyverna Therapeutics | $60M | 03 Aug 2023 | Berkeley, California, United States | ||
Kyverna Therapeutics | $85M | 26 Jan 2022 | Berkeley, California, United States | ||
OpGen | $17M | 07 Mar 2012 | Maryland, United States | ||
OpGen | $17M | 28 Sep 2010 | Maryland, United States |
